Newsbenzinga
Merck One of Top Large-Cap Biopharma Picks-Analyst
· Published
Article summary
Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
An excerpt from the original article.
Comments —
Loading comments…